Helix BioPharma Corp. (Helix; TSX,
FSE: "HBP") today announced the signing of an agreement with the National
Research Council of Canada's Institute for Biological Sciences (NRC-IBS), to
assist with the ongoing characterization of the lung cancer specific antibody
previously licensed to Helix for its L-DOS47 new drug candidate; as well as to
identify further novel tumor targeting antibodies.
